Iovance Biotherapeutics, Inc.
IOVAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Iovance Biotherapeutics, Inc. focuses on Biotechnology services and products. Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic. Valued at $1.83B, IOVA is a small-cap name in its sector. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
Market Cap
$1.83B
Beta
0.69
P/E (TTM)
—
P/E (Fwd)
-12.85
EPS (TTM)
$-0.92
EPS (Fwd)
$-0.32
ROE
-47.5%
ROA
-23.6%
Cash
$313.4M
Total Debt
$47.8M
Free CF
-$149.1M
52W Change
132.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $313.4M in cash comfortably exceeding the $47.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$149.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -47.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
IOVA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, IOVA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IOVA.